Qube Research & Technologies (QRT)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-60,459	Closed	-$254K	–	3221
2023 Q1	$254K	Buy	+60,459	New	+$314K	﹤0.01%	1839
2022 Q2	–	Sell	-162,309	Closed	-$758K	–	3371
2022 Q1	$758K	Buy	162,309 +124,683	+331%	+$372K	0.01%	1315
2021 Q4	$93K	Buy	37,626 +12,938	+52%	+$31.7K	﹤0.01%	2153
2021 Q3	$73K	Buy	+24,688	New	+$67.2K	﹤0.01%	1841
2021 Q2	–	Sell	-41,593	Closed	-$121K	–	3046
2021 Q1	$121K	Sell	41,593 -128,990	-76%	-$421K	﹤0.01%	1725
2020 Q4	$549K	Buy	+170,583	New	+$567K	0.01%	1081

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CTIC Position: Q2 2023 in Review

Qube Research & Technologies (QRT) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 60,459 shares — an estimated $254K sold.

Qube Research & Technologies (QRT) first reported a position in CTIC in Q4 2020 and held it in 6 quarters. The position peaked at $758K in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Qube Research & Technologies (QRT) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 60,459 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $254K.
Qube Research & Technologies (QRT) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 6 quarters.
Qube Research & Technologies (QRT)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $758K in Q1 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2023, filed 14 Aug 2023.